BioMarin Pharmaceutical (WBO:BMRN) E10: €0.01 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:BMRN BioMarin Pharmaceutical Inc WBO:BMRN
80 GF Score
Price €58.24
GF Value €73.06
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical E10?

BioMarin Pharmaceutical WBO:BMRN -2.77% 80 E10 is €0.01 as of Jun. 2026. GuruFocus rates WBO:BMRN with a GF Score™ of 80/100 and a GF Value™ of €73.06 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

BioMarin Pharmaceutical's adjusted earnings per share data for the three months ended in Jun. 2026 was €0.200. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.01 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 28.60% per year. During the past 5 years, the average E10 Growth Rate was 18.40% per year. During the past 10 years, the average E10 Growth Rate was -2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of BioMarin Pharmaceutical was 28.60% per year. The lowest was -63.90% per year. And the median was 6.50% per year.

As of today (2026-08-16), BioMarin Pharmaceutical's current stock price is €58.24. BioMarin Pharmaceutical's E10 for the quarter that ended in Jun. 2026 was €0.01. BioMarin Pharmaceutical's Shiller PE Ratio of today is 5,824.00.

During the past 13 years, the highest Shiller PE Ratio of BioMarin Pharmaceutical was 6734.00. The lowest was 5899.00. And the median was 5959.00.


BioMarin Pharmaceutical  (WBO:BMRN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BioMarin Pharmaceutical's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=58.24/0.01
=5,824.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of BioMarin Pharmaceutical was 6734.00. The lowest was 5899.00. And the median was 5959.00.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


BioMarin Pharmaceutical E10 Related Terms


BioMarin Pharmaceutical E10 Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical E10 Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.27 -1.22 -1.01 -0.77 -0.41

BioMarin Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.34 -0.41 -0.32 0.01

WBO:BMRN vs TECH, CYTK, SMMT: E10 Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Shiller PE Ratio falls into.


WBO:BMRN
80GF Score
BioMarin Pharmaceutical Inc WBO:BMRN
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioMarin Pharmaceutical's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.2/333.9520*333.9520
=0.200

Current CPI (Jun. 2026) = 333.9520.

BioMarin Pharmaceutical Quarterly Data

per share eps CPI Adj_EPS
201609 -0.196 241.428 -0.271
201612 -0.502 241.432 -0.694
201703 -0.084 243.801 -0.115
201706 -0.187 244.955 -0.255
201709 -0.059 246.819 -0.080
201712 -0.253 246.524 -0.343
201803 -0.211 249.554 -0.282
201806 -0.077 251.989 -0.102
201809 -5.999 252.439 -7.936
201812 -0.026 251.233 -0.035
201903 -0.283 254.202 -0.372
201906 -0.186 256.143 -0.243
201909 0.272 256.759 0.354
201912 0.072 256.974 0.094
202003 0.398 258.115 0.515
202006 -0.142 257.797 -0.184
202009 3.404 260.280 4.367
202012 0.099 260.474 0.127
202103 0.076 264.877 0.096
202106 0.058 271.696 0.071
202109 -0.170 274.310 -0.207
202112 -0.283 278.802 -0.339
202203 0.572 287.504 0.664
202206 0.142 296.311 0.160
202209 -0.040 296.808 -0.045
202212 -0.001 296.797 -0.001
202303 0.252 301.836 0.279
202306 0.268 305.109 0.293
202309 0.197 307.789 0.214
202312 0.101 306.746 0.110
202403 0.423 312.332 0.452
202406 0.511 314.175 0.543
202409 0.496 315.301 0.525
202412 0.611 315.605 0.647
202503 0.879 319.799 0.918
202506 1.066 322.561 1.104
202509 -0.136 324.800 -0.140
202512 -0.205 324.054 -0.211
202603 0.467 330.213 0.472
202606 0.200 333.952 0.200

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.01 mean?
BioMarin Pharmaceutical (WBO:BMRN) has a E10 of €0.01 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's E10 too high?
BioMarin Pharmaceutical's current E10 is €0.01. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's E10 compare to TECH and CYTK?
BioMarin Pharmaceutical's E10 of €0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current E10 is €0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (WBO:BMRN) is currently considered Modestly Undervalued. The stock's GF Value™ is €73.06, compared to a current price of €58.24 — trading 20.3% below its estimated fair value. The current E10 is €0.01. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For BioMarin Pharmaceutical (WBO:BMRN), the current E10 is €0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (WBO:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €58.24 is trading 20.3% below its estimated GF Value™ of €73.06. GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.

Key valuation signals for WBO:BMRN:

  • E10: €0.01
  • GF Value™: €73.06 vs. price of €58.24 (20.3% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the WBO:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score

Get the complete analysis for WBO:BMRN

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.24
Price
€73.06
GF Value